Gastrointestinal Laboratory, Department of Small Animal Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, 4474 TAMU, College Station, TX 77843, USA.
Department of Medicine, Faculty of Veterinary Science, University of Thessaly, Trikalon 224, 43100 Karditsa, Greece.
Vet Parasitol. 2014 Jul 14;203(3-4):326-30. doi: 10.1016/j.vetpar.2014.03.033. Epub 2014 Apr 12.
Canine leishmaniosis (CanL) caused by Leishmania infantum is an important zoonotic disease. One of the most commonly used drugs for the treatment of CanL is meglumine antimonate. Drugs of this class have been associated with pancreatitis and cardiotoxicity in humans infected with Leishmania spp. The aim of this study was to measure serum canine pancreatic lipase immunoreactivity (Spec cPL) and cardiac troponin I (cTnI) concentrations in dogs with leishmaniosis during treatment with meglumine antimonate, and to compare them with those of dogs with leishmaniosis not treated with this drug. A total of 30 non-uremic dogs with leishmaniosis, living in Greece, were prospectively enrolled into the study. Of the 30 dogs, 20 (Group A) were treated with a combination of meglumine antimonate (100mg/kg, SC, q24 h) and allopurinol (10mg/kg, PO, q12h) for 28 days, while 10 dogs (Group B) were treated with allopurinol alone (10mg/kg, PO, q12h) for 28 days. Blood samples were collected at timepoint 0 (before treatment) and at 14 and 28 days after the initiation of treatment. None of the dogs treated with meglumine antiomonate had a Spec cPL concentration suggestive of pancreatitis (≥ 400 μg/L) or clinical signs suggestive of pancreatitis at any of the timepoints. Similarly, none of the dogs treated with meglumine antiomonate had a serum cTnI concentration above the upper limit of the reference range (>0.5 ng/mL) or clinical evidence of cardiotoxicity at any of the 3 timepoints. In the present study, meglumine antimonate treatment in dogs with leishmaniosis did not result in clinical or laboratory evidence of either pancreatitis or cardiotoxicity.
犬利什曼病（CanL）由婴儿利什曼原虫引起，是一种重要的人畜共患病。治疗 CanL 最常用的药物之一是葡甲胺锑。该类药物已被证明可引起感染利什曼原虫的人类胰腺炎和心脏毒性。本研究的目的是测量在用葡甲胺锑治疗利什曼病的犬的血清犬胰腺脂肪酶免疫反应性（Spec cPL）和心肌肌钙蛋白 I（cTnI）浓度，并将其与未用该药物治疗的利什曼病犬进行比较。总共前瞻性纳入了 30 只患有利什曼病且无尿毒症的非尿毒症希腊犬。30 只犬中，20 只（A 组）用葡甲胺锑（100mg/kg，SC，q24 h）和别嘌醇（10mg/kg，PO，q12h）联合治疗 28 天，10 只犬（B 组）用别嘌醇单独治疗 28 天（10mg/kg，PO，q12h）。在治疗前（时间点 0）和治疗开始后 14 天和 28 天采集血样。在用葡甲胺锑治疗的犬中，没有犬的 Spec cPL 浓度提示胰腺炎（≥400μg/L）或任何时间点出现胰腺炎的临床症状。同样，在用葡甲胺锑治疗的犬中，没有犬的血清 cTnI 浓度超过参考范围上限（>0.5ng/mL）或任何 3 个时间点出现心脏毒性的临床证据。在本研究中，用葡甲胺锑治疗利什曼病犬不会导致胰腺炎或心脏毒性的临床或实验室证据。
